Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States
Background and objectiveThe EV-302 trial found that the combination of enfortumab vedotin (EV) with pembrolizumab significantly improved survival for patients with metastatic urothelial carcinoma (mUC). However, given the high cost of the drugs, there is a need to assess its value by considering bot...
שמור ב:
| Principais autores: | , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2024-09-01
|
| סדרה: | Frontiers in Immunology |
| נושאים: | |
| גישה מקוונת: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1464092/full |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|